### Indonesia

**Population 2018** 268 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
<td>316 (288–345)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–36)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>93 (67–99)</td>
<td>35 (33–37)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**
- New cases: 2.4% (1.8–3.3)
- Previously treated cases: 13% (9–18)

**TB case notifications, 2018**
- Total new and relapse: 563,879
  - % tested with rapid diagnostics at time of diagnosis: 12%
  - % with known HIV status: 37%
  - % pulmonary: 88%
  - % bacteriologically confirmed**: 50%
  - % children aged 0-14 years: 11%
  - % women: 37%
  - % men: 52%
- Total cases notified: 570,289

**Universal health coverage and social protection**
- TB treatment coverage (notified/estimated incidence), 2018: 67% (61–73)
- TB patients facing catastrophic total costs: 12% (10–13)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 12% (10–13)
- TB/HIV care in new and relapse TB patients, 2018: Number (%)
  - % with known HIV status who are HIV-positive: 10,174 5%
    - on antiretroviral therapy: 4,082 40%

**Drug-resistant TB care, 2018**
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 33%
  - New cases: 33%
  - Previously treated cases: 127%
- Laboratory-confirmed cases*: MDR/RR-TB: 9,038, XDR-TB: 80
- Patients started on treatment**: MDR/RR-TB: 4,194, XDR-TB: 59
- MDR/RR-TB cases tested for resistance to second-line drugs: 2,526

**Treatment success rate and cohort size**
- New and relapse cases registered in 2017: 85% 425,819
- Previously treated cases, excluding relapse, registered in 2017: 73% 4,934
- HIV-positive TB cases registered in 2017: 69% 7,966
- MDR/RR-TB cases started on second-line treatment in 2016: 48% 1,905
- XDR-TB cases started on second-line treatment in 2016: 21% 61

**TB preventive treatment, 2018**
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 10% (9.3–11)

**TB financing, 2019**
- National TB budget (US$ millions): 366
- Funding source: 30% domestic, 13% international, 57% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-18
Data: www.who.int/tb/data